Agent for treating fabry disease, analgesic for external use and perspiration accelerator

The technology of a therapeutic agent and an enhancer is applied in the field of therapeutic agents for Fabry disease, which can solve the problems of unclear analgesic effect and the like, and achieve the effects of low concentration of active ingredients, safe treatment and simple use.

Inactive Publication Date: 2018-10-23
OSAKA UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] In addition, non-patent literature 2 describes that the analgesic effect of oral rapamycin (sirolimus) in patients with neurofibroma is not clear and further research is required in the future

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for treating fabry disease, analgesic for external use and perspiration accelerator
  • Agent for treating fabry disease, analgesic for external use and perspiration accelerator
  • Agent for treating fabry disease, analgesic for external use and perspiration accelerator

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0085] Examples of methods for preparing external medicines include the following methods. (i) The gel can be prepared by gelling a solution containing rapamycin or a rapamycin derivative. (ii) An ointment can be prepared by mixing an ointment base with rapamycin or a rapamycin derivative. (iii) Patches, cataplasms, liniments, lotions, and creams can be prepared according to known methods.

[0086] Hereinafter, the gel and the ointment will be specifically described.

[0087] (I-A-1) Gel

[0088] As described above, the therapeutic agent for Fabry disease according to one embodiment of the present invention may be a gel obtained by gelling a solution containing rapamycin or a rapamycin derivative.

[0089] When gelling a solution containing rapamycin or a rapamycin derivative, it is only necessary to use a gelation inducer to gel the solution. Examples of gelation inducing agents include carboxyvinyl polymers, carboxymethylcellulose, aluminum hydroxide, bentonite and the l...

manufacture example

[0170] Production example: Preparation of gel containing rapamycin

[0171] Gels containing various concentrations of rapamycin were prepared. As a specific method, after adding and dissolving sirolimus (rapamycin) in ethanol, water (specifically, water for injection) was added and mixed to prepare a mixed solution. Carbopol (registered trademark) (specifically, Carbopol (registered trademark) 934P NF) was added to the mixed solution and mixed to prepare a homogeneous suspension. A neutralizer (specifically, tris) was added to the suspension and mixed to prepare a gel.

[0172] In addition, the components other than rapamycin in 1 g of the gel are 16 mg of Carbopol (registered trademark) 934PNF, 490 mg of water, 480-490 mg of ethanol, and 6 mg of tris.

[0173] More specifically, gels were prepared with the compositions of Production Examples 1 and 2 and Comparative Production Example 1 below.

manufacture example 1

[0174] Production Example 1: Gel containing 0.4% by weight of rapamycin (total weight 100 g)

[0175] Rapamycin 0.4g

[0176] Ethanol 48.4g

[0177] Water for injection 49g

[0178] Carbopol (registered trademark) 934P NF 1.6g

[0179] Trishydroxymethylaminomethane 0.6g.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to view more

Abstract

The agent for treating Fabry disease, analgesic for external use and perspiration accelerator according to one embodiment of the present invention comprise rapamycin or a rapamycin derivative.

Description

technical field [0001] The invention relates to a therapeutic agent for Fabry's disease, an analgesic for external use and a sweating enhancer. Background technique [0002] Fabry disease is a genetic disorder resulting from the congenital absence of a lysosomal enzyme, α-galactosidase (α-Gal), resulting in its substrate, trihexosylceramide (GL-3) or galactosidase Lactosebiosylceramide (GL-2), blood type B glycolipids and other glycolipids with galactose at the non-reducing end are stored in lysosomes, and then stored in vascular endothelial cells, cardiomyocytes, ganglion All kinds of cells headed by cells, thus showing various clinical symptoms related to the organs of the whole body. [0003] Various symptoms such as cardiac dysfunction, renal dysfunction, neurological symptoms accompanied by pain, angiokeratoma, and corneal opacity occur due to organ damage due to accumulation of GL-3 and the like. [0004] Therefore, symptoms of Fabry's disease, which is considered to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/436A61P3/00A61P25/04A61P29/00
CPCA61K31/436A61P3/00A61P17/00A61P25/04A61P29/00A61K31/675A61P43/00
Inventor 金田真理片山一朗
Owner OSAKA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap